Annexes to COM(2020)659 - EU position in the Commission on Narcotic Drugs om adding substances under the Single Convention on Narcotic Drugs and the Convention on Psychotropic Substances - Main contents
Please note
This page contains a limited version of this dossier in the EU Monitor.
| dossier | COM(2020)659 - EU position in the Commission on Narcotic Drugs om adding substances under the Single Convention on Narcotic Drugs and the ... |
|---|---|
| document | COM(2020)659  |
| date | November 23, 2020 |
Position to be taken by the Member States that are members of the Commission on Narcotic Drugs (CND), acting jointly in the interest of the Union, at the reconvened sixty-third session of the CND, which is scheduled to take place from 2 to 4 December 2020:
| (1) | cannabis and cannabis resin are to be deleted from Schedule IV of the Convention on Narcotic Drugs (1); |
| (2) | dronabinol and its stereoisomers (delta-9-tetrahydrocannabinol) are to be added to Schedule I of the Convention on Narcotic Drugs and, if that recommendation is adopted, to be deleted from Schedule II of the Convention on Psychotropic Substances; |
| (3) | tetrahydrocannabinol (isomers of delta-9-tetrahydrocannabinol) is to be added to Schedule I of the Convention on Narcotic Drugs, subject to the CND’s adoption of the recommendation to add dronabinol and its stereoisomers (delta-9-tetrahydrocannabinol) to Schedule I of the Convention on Narcotic Drugs, and, if that recommendation is adopted, is to be deleted from Schedule I of the Convention on Psychotropic Substances; |
| (4) | the term ‘extracts and tinctures’ is to be deleted from Schedule I of the Convention on Narcotic Drugs; |
| (5) | the footnote reading ‘Preparations containing predominantly cannabidiol and not more than 0.2 percent of delta-9-tetrahydrocannabinol are not under international control.’ is not to be added to the entry for cannabis and cannabis resin in Schedule I of the Convention on Narcotic Drugs; |
| (6) | preparations produced either by chemical synthesis or as preparation of cannabis, that are compounded as pharmaceutical preparations with one or more other ingredients and in such a way that delta-9-tetrahydrocannabinol (dronabinol) cannot be recovered by readily available means or in a yield which would constitute a risk to public health, are not to be added to Schedule III of the Convention on Narcotic Drugs. |
In order to ensure coherence of the scheduling and to avoid the risk that a substance is scheduled under the Convention on Narcotic Drugs as well as under the Convention on Psychotropic Substances, the Member States that are members of the CND can accept a joint vote on the recommendations concerned.
(1) They continue to be listed in Schedule I of that Convention.